Abstract
There is accumulating clinical evidence that 5-aminosalicylic acid (5-ASA), a primary metabolite of sulfasalazine (SAS), represents the therapeutic active moiety of the azo-compound SAS in the treatment of chronic inflammatory bowel disease (IBD). Since it is presumed that 5-ASA acts from the lumen of the intestine, it is important to know how much 5-ASA is released from its special galenic formulations. After liberation of 5-ASA in the terminal ileum (only slow release oral preparations of 5-ASA) and colon (5-ASA suppositories and enemas), 5-ASA is only partly absorbed. A major part of this 5-ASA is presystemically eliminated, eg, N-acetylated during its first passage through the intestinal mucosa and liver. Mean steady state plasma levels of unchanged 5-ASA are rather low (range 0.02 to 1.2 μg/ml) whereas those of Ac-5-ASA are always higher (range 0.1 to 2.9 μg/ml). This is due to the rapid elimination of 5-ASA (t1/2=0.4 to 2.4h) and the slightly slower renal excretion of the Ac-5-ASA (t1/2=6 to 9h, renal clearance=200 to 300 ml/min). The knowledge of the pharmacokinetic properties of 5-ASA from different drug formulations might contribute to a better understanding of its mode of action in IBD.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Klotz U: Clinical efficacy of oral 5-aminosalicylic acid in the treatment of inflammatory bowel disease. Am J Gastroenterol 80:660, 1985
Friedman G: Sulfasalazine and new analogues. Am J Gastroenterol 81:141–144, 1986
Klotz U: Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 10:285–302, 1985
Klotz U, Maier KE, Fischer C, Bauer KH: A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease: Biopharmaceutic and clinical pharmacokinetic characteristics. Arzneim-Forsch 35:636–639, 1985
Azad Khan KA, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet II:892–895, 1977
Klotz U, Maier K, Fischer C, Heinkel K: Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med 303:1499–1502, 1980
van Hees PAM, Bakker JH, von Tongeren JHM: Effect of sulfapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: A study to determine the active therapeutic moiety of sulphasalazine. Gut 21:632–635, 1980
Campieri M, Lanfranchi GA, Bazzocci G, Brignola C, Sarti F, Franzin G, Battocchia A, Labo G, dal Monte PR: Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet II:270–271, 1981
Maier K, Fischer C, Klotz U, Heinkel K: 5-Aminosalicylsäure bei Colitis ulcerosa und Morbus Crohn. Dtsch Med Wschr 107:1131–1134, 1982
Maier K, Fischer C, Klotz U: 5-Aminosalicylsäure—ein neues Behandlungsprinzip bei Colitis ulcerosa und Morbus Crohn. Verdauungskrankheiten 1:62–65, 1983
Janssens J, Geboes K, Delanote C, Vantrappen G: 5-Aminosalicylic acid (5-ASA) enemas are effective in patients with resistant rectosigmoiditis. Gastroenterology 84:1198, 1983
Bondesen S, Nielsen OH, Jacobsen O, Rasmussen SN, Hansen SH, Halskoov S, Binder V, Hvidberg EF: 5-Aminosalicylic acid enemas in patients with active ulcerative colitis. Scan J Gastroenterol 19:677–682, 1984
Barber GB, Lee DE, Antonioli DA, Peppercorn MA: Refractory distal ulcerative colitis responsive to 5-aminosalicylic enemas. Amer J Gastroenterol 80:612–614, 1985
Sutherland LR, Martin F: 5-Aminosalicylsäure in der Behandlung der distalen Colitis ulcerosa.In Therapie chronisch entzündlicher Darmerkrankungen, K Ewe, H Fahrländer (eds). Stuttgart/New York, Schattauer Verlag, 1986, p. 257
Friedman LW, Richter JM, Kirkham SE, deMonaco H, May RJ: 5-Aminosalicylic acid in refractory distal ulcerative colitis: A randomized controlled trial. Gastroenterology 188:1388, 1985
Hanauer SB, Schultz PA, Kirsner JB: Treatment of refractory proctitis with 5-ASA enemas. Gastroenterology 88:1412, 1985
Dew MJ, Hughes P, Harries AD, Williams G, Evans BK, Rhodes J: Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Brit Med J 285:1012, 1982
Dew MJ, Ryder REJ, Evans N, Evans BK, Rhodes J: Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis. Brit J Clin Pharmacol 16:185–187, 1983
Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskow S, Flachs H: 5-Aminosalicylic acid in a slow-release preparation: Bioavailability, plasma level, and excretion in humans. Gastroenterology 83:1062–1070, 1982
Saverymuttu S, Keshavarzian A, Gupta S, Donovan B, Hodgson HJ: Evaluation of short term treatment of Crohn's disease with slow release 5-aminosalicylic acid. Gut 25:A552, 1984
Austin CA, Cann CA, Jones TH, Holdsworth CD: Exacerbation of diarrhea and pain in patients treated with 5-aminosalicylic acid for ulcerative colitis. Lancet I:917–918, 1984
Maier K, Frühmorgen P, Bode JCh, Heller, Th, von Gaisberg U, Klotz U: Erfolgreiche Akutbehandlung chronisch-entzündlicher Darmerkrankungen mit oraler 5-Aminosalicylsäure. Dtsch Med Wschr 110:363–368, 1985
Habal FM, Greenberg GR: Oral 5-aminosalicylic acid in the treatment of ulcerative colitis. Gastroenterology 88:1409, 1985
Schröder KW, Tremaine WJ: Corticosteroid dependent chronic ulcerative colitis: Favourable response to oral 5-aminosalicylic acid. Gastroenterology 88:1388, 1985
d'Albasio G, Pacini F, Innocenti S, Milla M, Ghetti A, Morettini A: Long-term maintenance therapy in ulcerative colitis-controlled trial with 5-aminosalicylic acid (5-ASA) enemas. Dig Dis Sci 31 (Suppl):319S, 1986
Dew MJ, Harries AD, Evans N, Evans BK, Rhodes J: Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high dose by mouth. Brit Med J 287:23–24, 1983
Campieri M, Lanfranchi GA, Brignola C, Bazzocchi G, Minguzzi MR, Calari MT: 5-Aminosalicylic acid as rectal enema in ulcerative colitis patients unable to take sulphasalazine. Lancet I:403, 1984
Anttilla PM, Välimäki M, Pentikäinen PJ: Pure-red-cell aplasia associated with sulphasalazine but not 5-aminosalicylic acid. Lancet II:1006, 1985
Donald IP, Wilkinson SP: The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasazine. Postgrad Med J 61:1047–1048, 1985
Rasmussen SN, Binder V, Maier K, Bondesen S, Fischer C, Klotz U, Hansen SH, Hvidberg EF: Treatment of Crohn's disease with peroral 5-aminosalicylic acid. Gastroenterology 85:1350–1353, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Klotz, U., Maier, K.E. Pharmacology and pharmacokinetics of 5-aminosalicylic acid. Digest Dis Sci 32 (Suppl 12), S46–S50 (1987). https://doi.org/10.1007/BF01312463
Issue Date:
DOI: https://doi.org/10.1007/BF01312463